Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Appointment of CFO
Paris, France, and Eastleigh and Manchester, UK - 2 January - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Steve Gibson as Chief Financial Officer with immediate effect. Mr Gibson will become a Board Director of the Company, subject to shareholder approval, at the Company's Annual General Meeting.
Steve joined Novacyt in 2017 and has served as Group Finance Director since 2020. Prior to joining Novacyt, Steve spent over 10 years in various finance departments at Hewlett-Packard and then Hewlett Packard Enterprise in positions of increasing seniority. Steve is a Chartered Management Accountant (CIMA) and has more than 18 years of international commercial experience.
Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted to welcome Steve as our CFO. He has impressed us with his financial and operational expertise and was instrumental in the acquisition of Yourgene Health plc as well as delivering the strategic changes to the Company over the last two years. The Board looks forward to working with him as we continue to execute our growth strategy."
Additional Disclosures Required under the AIM Rules for Companies
Steven Michael Gibson (aged 41) has held the following directorship or partnerships in the past five years:
| Current directorships/partnerships | Previous directorships/partnerships (last five years) |
| Lab21 Healthcare Limited Biotec Laboratories Limited Primer Design Limited Microgen Bioproducts Limited Novacyt UK Holdings Limited IT-IS International Limited Delta Diagnostics (UK) Limited Yourgene Health Limited Yourgene Health UK Limited Yourgene Genomic Services Limited Elucigene Limited Yourgene Health Canada Investments Yourgene Health Canada Holdings Yourgene Health Inc
| |
Mr Gibson and persons closely associated (as defined under MAR) with Mr Gibson currently hold 9,116 ordinary shares of €1/15 each in the Company.
Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.
Contacts
| Novacyt SA | ||||
| James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer | Via Walbrook PR | |||
| | | |||
| SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
| Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) | | |||
| | | |||
| Deutsche Numis (Joint Broker) | +44 (0)20 7260 1000 | |||
| Freddie Barnfield / Duncan Monteith / Michael Palser | | |||
| | | |||
| Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit | +33 (1) 42 22 10 10 | |||
| | | |||
| Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings | +44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7796 794 663/ +44 (0)7980 541 893 + 44 (0)7867 984 082 / +44 (0)7407 804 654 | |||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei (divestment pending), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
